Takeda Oncology
James Tan is an experienced professional in the oncology sector, currently serving as the Disease Area Strategy Business Lead for Hematology at Takeda Oncology since February 2018. In this role, James leads the Hematology Integrated Disease Area Strategy, driving collaboration across global teams and focusing on business development opportunities, disease area strategies, and input for global program teams. Previous positions at Takeda include Global New Product Planning Lead for oncology pipeline assets and Oncology Brand Director for the Growth & Emerging Markets region, where James successfully managed a portfolio exceeding $300 million. With a strong background at Novartis Oncology as Business Franchise Head and in various marketing roles, along with earlier experience in regulatory affairs and as a pharmacist, James holds a Bachelor of Pharmacy from Universiti Sains Malaysia.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.